Analyze the Cardiovascular Benefits of the Different GLP-1 Agonists

August 2019

Dulaglutide (Trulicity) will be the third GLP-1 agonist to show CV benefits in some patients with type 2 diabetes.

It joins semaglutide (Ozempic) and liraglutide (Victoza). All three lower CV risk in type 2 patients with CV disease or at high CV risk.

Each of these meds also seems to slow progression to albuminuria...but none have been shown to delay dialysis.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote